Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7110095 | 0.79 | MTAP (0.34) | — | |
| SCHEMBL7108600 | 0.74 | TYMP (0.41) | MEN1LMNAKMT2A | |
| SCHEMBL7103584 | 0.73 | PNP (0.44) | — | |
| SCHEMBL26054854 | 0.70 | TOP1 (0.31) | — | |
| SCHEMBL7103540 | 0.68 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL7650963 | 0.66 | KMT2A (0.39) | MEN1LMNAKMT2A | |
| SCHEMBL14199854 | 0.65 | LMNA (0.48) | LMNA | |
| SCHEMBL7107855 | 0.65 | HSD17B10 (0.47) | MEN1LMNAKMT2A | |
| SCHEMBL7654981 | 0.63 | PNP (0.41) | — | |
| SCHEMBL5042295 | 0.63 | NOS3 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001944-B1 | PYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-10-01 | — | — | EP | claimed |
| US-6399613-B1 | N,N'-BIS(2-HYDROXYETHYL)PYRAZINE-2,5- OR -2,6-DICARBOXAMIDE; DIABETES | AVENTIS PHARMA S.A. (FR) | 2002-06-04 | — | — | US | claimed |
| US-6399613-B1 | N,N'-BIS(2-HYDROXYETHYL)PYRAZINE-2,5- OR -2,6-DICARBOXAMIDE; DIABETES | AVENTIS PHARMA S.A. (FR) | 2002-06-04 | — | — | US | disclosed |